Telcare provides a cellular-enabled blood glucose meter, a diabetes mobile application and a HIPAA-compliant cloud platform called Telserve. The Telserve cloud proactively delivers messages and reminders, offers personalized education, and captures diagnostic data while keeping patients’ doctors updated. The company’s product suite is focused on diabetes care and remote monitoring. Telcare intends to use the new funding to broaden its impact in diabetes and to expand the platform into related chronic conditions. The company is led by CEO Andrew Flanagan. Telcare is based in Bethesda, MD. Telcare develops a wireless glucose monitoring system centered on a wireless glucose meter with two-way messaging that transmits to an FDA-cleared care management server. The company also offers a suite of iPhone and Android apps to enable family members to follow the progress of loved ones with diabetes. Telcare was founded in 2008 by David Bjork, John R. Dwyer, Jr. (Chairman), and Jonathan C. Javitt, M.D., M.P.H. (CEO and Vice Chairman), and is based in Bethesda, MD. The company intends to use new capital for marketing and sales efforts, research and development initiatives, and ongoing operations. Telcare recently raised $25.5M in Series B equity funding led by Sequoia Capital with participation from Qualcomm through its Qualcomm Life Fund.

Total raised

$58M

Funding rounds

2

Latest round

Series C

Latest activity

Oct 2014